234 related articles for article (PubMed ID: 27780916)
1. Efficient generation of antigen-specific CTLs by the BAFF-activated human B Lymphocytes as APCs: a novel approach for immunotherapy.
Yiwen Z; Shilin G; Yingshi C; Lishi S; Baohong L; Chao L; Linghua L; Ting P; Hui Z
Oncotarget; 2016 Nov; 7(47):77732-77748. PubMed ID: 27780916
[TBL] [Abstract][Full Text] [Related]
2. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
3. B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC.
Ivanov R; Aarts T; Hagenbeek A; Hol S; Ebeling S
Cytotherapy; 2005; 7(1):62-73. PubMed ID: 16040385
[TBL] [Abstract][Full Text] [Related]
4. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
[TBL] [Abstract][Full Text] [Related]
5. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
6. An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in
Zhang L; Song S; Jin X; Wan X; Shahzad KA; Pei W; Zhao C; Shen C
Cancer Immunol Res; 2019 Jul; 7(7):1188-1201. PubMed ID: 31113806
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy.
Wu C; Liu Y; Zhao Q; Chen G; Chen J; Yan X; Zhou YH; Huang Z
Virol J; 2010 Dec; 7():370. PubMed ID: 21176236
[TBL] [Abstract][Full Text] [Related]
8. Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo.
Shen S; Xu Z; Qian X; Ding Y; Yu L; Liu B
Exp Oncol; 2007 Jun; 29(2):137-43. PubMed ID: 17704747
[TBL] [Abstract][Full Text] [Related]
9. B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses.
Rossetti RAM; Lorenzi NPC; Yokochi K; Rosa MBSF; Benevides L; Margarido PFR; Baracat EC; Carvalho JP; Villa LL; Lepique AP
PLoS One; 2018; 13(7):e0199034. PubMed ID: 29975708
[TBL] [Abstract][Full Text] [Related]
10. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.
Schoenberger SP; Toes RE; van der Voort EI; Offringa R; Melief CJ
Nature; 1998 Jun; 393(6684):480-3. PubMed ID: 9624005
[TBL] [Abstract][Full Text] [Related]
11. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
Schultze JL; Michalak S; Seamon MJ; Dranoff G; Jung K; Daley J; Delgado JC; Gribben JG; Nadler LM
J Clin Invest; 1997 Dec; 100(11):2757-65. PubMed ID: 9389740
[TBL] [Abstract][Full Text] [Related]
12. K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.
Caruana I; Weber G; Ballard BC; Wood MS; Savoldo B; Dotti G
Clin Cancer Res; 2015 Jul; 21(13):2952-62. PubMed ID: 25691731
[TBL] [Abstract][Full Text] [Related]
13. A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells.
Garcia-Marquez MA; Shimabukuro-Vornhagen A; Theurich S; Kochanek M; Weber T; Wennhold K; Dauben A; Dzionek A; Reinhard C; von Bergwelt-Baildon M
Cytotherapy; 2014 Nov; 16(11):1537-1544. PubMed ID: 25287602
[TBL] [Abstract][Full Text] [Related]
14. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
Front Immunol; 2021; 12():674276. PubMed ID: 34566953
[TBL] [Abstract][Full Text] [Related]
15. Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.
Yang S; Tsang KY; Schlom J
Clin Cancer Res; 2005 Aug; 11(15):5603-15. PubMed ID: 16061879
[TBL] [Abstract][Full Text] [Related]
16. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
17. Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells.
Palena C; Zhu M; Schlom J; Tsang KY
Blood; 2004 Jul; 104(1):192-9. PubMed ID: 15010371
[TBL] [Abstract][Full Text] [Related]
18. Photochemical Treatment of
Ye J; Yang C; Cai Z; Shi W; Yu H
Mediators Inflamm; 2018; 2018():4167652. PubMed ID: 30327581
[No Abstract] [Full Text] [Related]
19. Antigen-presenting B cells: efficient uptake and presentation by activated B cells for induction of cytotoxic T lymphocytes against vesicular stomatitis virus.
Ciavarra RP; Burgess DH
Cell Immunol; 1988 Jun; 114(1):27-40. PubMed ID: 2836071
[TBL] [Abstract][Full Text] [Related]
20. Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines.
Chakraborty NG; Li L; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
J Immunol; 1999 May; 162(9):5576-83. PubMed ID: 10228040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
